



ELSEVIER



The thalidomide analog 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanoic acid improves the biliary cirrhosis in the rat

Eduardo Fernández-Martínez^{a,*}, Nury Pérez-Hernández^a, Pablo Muriel^b,
Víctor Pérez-Álvarez^b, Mineko Shibayama^c, Víctor Tsutsumi^c

^aCentro de Investigación en Biología de la Reproducción, Área Académica de Medicina, I.C.Sa.-Universidad Autónoma del Estado de Hidalgo, Hidalgo, Mexico

^bSección Externa de Farmacología, Cinvestav-I.P.N., Apdo. Postal 14-740, D.F., Mexico

^cDepartamento de Patología Experimental, Cinvestav-I.P.N., Apdo. Postal 14-740, D.F., Mexico

Received 17 September 2008; accepted 4 November 2008

Abstract

Chronic cholestasis and cholangitis may lead to the last phase known as biliary cirrhosis, characterized by cellular necrosis, apoptosis, tissue damage, local regeneration, inflammation and fibrosis. Such events are mediated by cytokines. Thalidomide and its analogs have shown to be effective immunomodulatory and hepatoprotective agents. The aim of this work was to evaluate the hepatoprotective properties of a thalidomide analog, the 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanoic acid (PDA), on bile duct obstruction-induced cirrhosis. Vehicle or PDA (67 mg/kg) was orally administered twice a day to sham (Sham) or bile duct-ligated (BDL) male Wistar rats. The animals were sacrificed 28 days after treatments. Alkaline phosphatase (AP), γ -glutamyl transpeptidase (GGTP) and alanine aminotransferase (ALT) enzyme activities as well as direct and total bilirubins concentration were determined in plasma. Lipid peroxidation (LP), glycogen and collagen were quantified in liver; in addition, histopathology was performed. PDA improved cholestasis, necrosis and fibrosis by significantly diminishing most of liver injury markers ($P < 0.05$). Histopathology also showed remarkable liver damage amelioration. PDA effectiveness may be due to its water-solubility, stability, phosphodiesterase-4 inhibitory and immunomodulatory actions. Thalidomide and its analogs seem to be promising drugs for further treatment of biliary cirrhosis.

© 2008 Elsevier GmbH. All rights reserved.

Keywords: Bile duct ligation; Cholestasis; Cirrhosis; Fibrosis; Liver; Necrosis; Thalidomide; Thalidomide analogs

Introduction

Cholestasis is defined as a disorder of cholepoiesis and bile secretion as well as mechanical or functional stoppage of the bile flow in intrahepatic or extrahepatic bile ducts, with bile components passing into the blood. Persistent cholestasis with concomitant inflammatory and connective tissue reactions as well as all forms of chronic cholangitis may lead to irreversible cholestasis

*Corresponding author at: Laboratory of Medicinal Chemistry and Pharmacology, Academic Group of Biology of Reproduction, Academic Area of Medicine of Institute of Health Sciences (I.C.Sa.), Autonomous University of Hidalgo's State (UAEH), Calle Dr. Eliseo Ramírez Ulloa no. 400, Colonia Doctores, Pachuca, Hidalgo, México. C.P. 42090, Mexico. Tel.: +52 77117172000x4510, 4512.

E-mail addresses: efernan@uaeh.reduaeh.mx, tomedymf@hotmail.com (E. Fernández-Martínez).